Schizophrenia and Macroprolactinoma: Is There a Deep Link?

3Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Prolactinomas are the most common type of functional pituitary tumors. Dopamine agonists is the most important drugs used in prolactinoma,have antagonistic effect with antipsychotic drugs used in schizophrenia. Conversely, dopamine antagonist drugs increase prolactin in patients with simultaneous schizophrenia. In the present case, we report a 29-year-old single male with schizophrenia who treated for 8 years with risperidone and presented with macroprolactinoma. Iatrogenic hyperprolactinemia is a well-known side effect of dopamine antagonist drugs for treatment in a patient with schizophrenia. On the other hand, it appears these drugs have the other side effects, such as drug- induced prolactinoma or boost growth.

Cite

CITATION STYLE

APA

Bamarinejad, A., Nasiri, S., Bamarinejad, F., Salehidoost, R., & Zare-Farashbandi, E. (2020). Schizophrenia and Macroprolactinoma: Is There a Deep Link? Advanced Biomedical Research, 9(1), 38. https://doi.org/10.4103/abr.abr_96_20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free